<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01737398</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 420915-CS2</org_study_id>
    <nct_id>NCT01737398</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of IONIS-TTR Rx in Familial Amyloid Polyneuropathy</brief_title>
  <official_title>A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of IONIS-TTR Rx given for 65
      weeks in patients with Familial Amyloid Polyneuropathy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Familial Amyloid Polyneuropathy (FAP) is a rare, hereditary disease caused by mutations in
      the transthyretin (TTR) protein. TTR is made by the liver and secreted into the blood. TTR
      mutations cause it to misfold and deposit in multiple organs causing FAP.

      IONIS-TTR Rx is an antisense drug that is designed to decrease the amount of mutant and
      normal TTR made by the liver. It is predicted that decreasing the amount of TTR protein will
      result in a decrease in the formation of TTR deposits, and thus slow or stop disease
      progression.

      The purpose of this study is to determine if IONIS-TTR Rx can slow or stop the nerve damage
      caused by TTR deposits. This study will enroll late Stage 1 and early Stage 2 FAP patients.
      Patients will receive either IONIS-TTR Rx or placebo for 65 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2012</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of IONIS-TTR Rx as measured by change from baseline in the modified Neuropathy Impairment Score +7</measure>
    <time_frame>65 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of IONIS-TTR Rx as measured by change from baseline in the Norfolk Quality of Life Diabetic Neuropathy questionnaire</measure>
    <time_frame>65 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of IONIS-TTR Rx based on the change from baseline in the following measures:</measure>
    <time_frame>65 weeks</time_frame>
    <description>Modified Body Mass Index and Body Mass Index
Individual components of the mNIS+7
NIS+7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effect of IONIS-TTR Rx based on the change from baseline in transthyretin and retinol binding protein 4</measure>
    <time_frame>65 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>FAP</condition>
  <condition>Familial Amyloid Polyneuropathy</condition>
  <condition>TTR</condition>
  <condition>Transthyretin</condition>
  <condition>Amyloidosis</condition>
  <arm_group>
    <arm_group_label>IONIS-TTR Rx</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS-TTR Rx</intervention_name>
    <description>300 mg IONIS-TTR Rx administered subcutaneously 3 times on alternate days in the first week and then once-weekly for 64 weeks.</description>
    <arm_group_label>IONIS-TTR Rx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered subcutaneously 3 times on alternate days in the first week and then once-weekly for 64 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage 1 and Stage 2 FAP patients with the following:

               1. NIS score within protocol criteria

               2. Documented transthyretin variant by genotyping

               3. Documented amyloid deposit by biopsy

          -  Females of child-bearing potential must use appropriate contraception and must be
             non-pregnant and non-lactating. Males engaged in relations of child-bearing potential
             must use appropriate contraception

        Exclusion Criteria:

          -  Low Retinol level at screen

          -  Karnofsky performance status ≤50

          -  Poor Renal function

          -  Known type 1 or type 2 diabetes mellitus

          -  Other causes of sensorimotor or autonomic neuropathy (e.g., autoimmune disease)

          -  If previously treated with Vyndaqel®, must have discontinued treatment for 2 weeks
             prior to Study Day 1. If previously treated with Diflunisal, must have discontinued
             treatment for 3 days prior to Study Day 1

          -  Previous treatment with any oligonucleotide or siRNA within 12 months of screening

          -  Prior liver transplant or anticipated liver transplant within 1 yr of screening

          -  New York Heart Association (NYHA) functional classification of ≥3

          -  Acute Coronary Syndrome or major surgery within 3 months of screening

          -  Known Primary or Leptomeningeal Amyloidosis

          -  Anticipated survival less than 2 years

          -  Have any other conditions in the opinion of the investigator which could interfere
             with the patient participating in or completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>82 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine - Amyloid Treatment &amp; Research Program</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center - The Neurological Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FLENI</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal University of Rio de Janeiro - University Hospital</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>CEP 21941913</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AACD</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNIFESP</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor - Department of Neurology</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bicetre Aphp French Referral Center for FAP/Cornamyl Network</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKM; Universitätsklinikum Münster, Klinik für Transplantationsmedizin</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi Di Messina - Azienda Ospedaliera Universitaria Policlinico &quot;Gaetano Martino&quot;</name>
      <address>
        <city>Messina</city>
        <state>Sicily</state>
        <zip>98124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro per lo Studio e la Cura delle Amiloidosi Sistemiche - Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHLN - Hospital de Santa Maria</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHP-HGSA, Unidade Clinica de Paramiloidose</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D' Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London - National Amyloidosis Centre</name>
      <address>
        <city>London</city>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
  </removed_countries>
  <link>
    <url>http://www.ttrstudy.com</url>
    <description>For more information about the drug IONIS-TTR Rx and TTR Amyloidosis click here</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2012</study_first_submitted>
  <study_first_submitted_qc>November 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <disposition_first_submitted>April 25, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>April 25, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 27, 2018</disposition_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FAP</keyword>
  <keyword>Familial Amyloid Polyneuropathy</keyword>
  <keyword>TTR</keyword>
  <keyword>Transthyretin</keyword>
  <keyword>Amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Amyloid Neuropathies</mesh_term>
    <mesh_term>Amyloid Neuropathies, Familial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

